Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Third Party Open, Multiple Dose Escalation, Single Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered ELX-02 in Independent Consecutive Cohorts of Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Third Party Open, Multiple Dose Escalation, Single Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered ELX-02 in Independent Consecutive Cohorts of Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exaluren (Primary)
  • Indications Cystic fibrosis; Cystinosis
  • Focus Adverse reactions
  • Sponsors Eloxx Pharmaceuticals

    • Most Recent Events

    • 26 Jan 2021 According to an Eloxx Pharmaceuticals media release, scientific manuscript on the results from this study was published in the Journal of Clinical Pharmacology in Drug Development.
    • 31 Oct 2019 Results presented in the Eloxx Pharmaceuticals Media Release.
    • 31 Oct 2019 According to a Eloxx Pharmaceuticals media release, data from this trial were presented at the Eloxx Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top